Figure 7.

EphA2-b-CAR-T treatment combined with PD1 blockade exhibited enhanced antitumor activity. U251 and U373 cells were transiently transfected with one of the siRNAs to knock down the expression of IFNGR1, IFNGR2 or PG-L1 separately (a and b), and then the cells were subjected to an in vitro killing assay at an E:T = 1:1. The cell lysis rates were determined by detecting luciferase activity (c). NOD-SCID mice were injected subcutaneously with 1 × 10⁷ U251.eGFP.Luc cells to construct a xenograft mouse model. Five days post-tumor xenograft, mice were treated with a total of 3 × 10⁷ CAR-T cells or non-transduced control T cells peritumorally, followed by peritumoral (p.t.) administration of 200 μg PD1 antibody. On day 13, the mice were administered a second dose of PD1antibody, and tumor growth was monitored using IVIS (D, E, and F)